These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18083027)

  • 1. In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand.
    Atatreh N; Stojkoski C; Smith P; Booker GW; Dive C; Frenkel AD; Freeman S; Bryce RA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1217-22. PubMed ID: 18083027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
    Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
    J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
    Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
    Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of EVH1, a novel proline-rich ligand-binding module involved in cytoskeletal dynamics and neural function.
    Fedorov AA; Fedorov E; Gertler F; Almo SC
    Nat Struct Biol; 1999 Jul; 6(7):661-5. PubMed ID: 10404224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and specificity studies of small-molecule ligands for SH3 protein domains.
    Inglis SR; Stojkoski C; Branson KM; Cawthray JF; Fritz D; Wiadrowski E; Pyke SM; Booker GW
    J Med Chem; 2004 Oct; 47(22):5405-17. PubMed ID: 15481978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening of Src kinase inhibitors.
    Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
    Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E
    J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
    Nam NH; Ye G; Sun G; Parang K
    J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
    Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
    Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation.
    Martín-García JM; Luque I; Mateo PL; Ruiz-Sanz J; Cámara-Artigas A
    FEBS Lett; 2007 May; 581(9):1701-6. PubMed ID: 17418139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.
    Boschelli DH; Wu B; Ye F; Wang Y; Golas JM; Lucas J; Boschelli F
    J Med Chem; 2006 Dec; 49(26):7868-76. PubMed ID: 17181170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Fluoroproline derivative peptides: effect on PPII conformation and SH3 affinity.
    Ruzza P; Siligardi G; Donella-Deana A; Calderan A; Hussain R; Rubini C; Cesaro L; Osler A; Guiotto A; Pinna LA; Borin G
    J Pept Sci; 2006 Jul; 12(7):462-71. PubMed ID: 16506148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent dipeptide inhibitors of the pp60c-src SH2 domain.
    Pacofsky GJ; Lackey K; Alligood KJ; Berman J; Charifson PS; Crosby RM; Dorsey GF; Feldman PL; Gilmer TM; Hummel CW; Jordan SR; Mohr C; Shewchuk LM; Sternbach DD; Rodriguez M
    J Med Chem; 1998 May; 41(11):1894-908. PubMed ID: 9599239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
    Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK
    Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
    Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
    Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel aminomethylindole derivatives as inhibitors of pp60c-Src tyrosine kinase: synthesis and biological activity.
    Işgör YG; Kiliç Z; Olgen S
    Chem Biol Drug Des; 2008 Dec; 72(6):599-604. PubMed ID: 19090928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the activity of pp60(c-src) protein tyrosine kinase inhibitors.
    Prabhu NV; Siddiqui SA; McMurray JS; Pettitt BM
    Biopolymers; 2001 Sep; 59(3):167-79. PubMed ID: 11391566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of the differential binding of the SH3 domains of Grb2 adaptor to the guanine nucleotide exchange factor Sos1.
    McDonald CB; Seldeen KL; Deegan BJ; Farooq A
    Arch Biochem Biophys; 2008 Nov; 479(1):52-62. PubMed ID: 18778683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based synthetic mimicry of discontinuous protein binding sites: inhibitors of the interaction of Mena EVH1 domain with proline-rich ligands.
    Hunke C; Hirsch T; Eichler J
    Chembiochem; 2006 Aug; 7(8):1258-64. PubMed ID: 16810654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallization by capillary counter-diffusion and structure determination of the N114A mutant of the SH3 domain of Abl tyrosine kinase complexed with a high-affinity peptide ligand.
    Cámara-Artigas A; Palencia A; Martínez JC; Luque I; Gavira JA; García-Ruiz JM
    Acta Crystallogr D Biol Crystallogr; 2007 May; 63(Pt 5):646-52. PubMed ID: 17452790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.